skip to the content

Powerfull symptom control

"[Tarceva] erlotinib not only improves survival in previously treated patients with NSCLC, but also improves tumor-related symptoms and important aspects of QOL." [1]

 
Enlarge image

Patients receiving Tarceva had significantly longer median time to deterioration of pain, cough and dyspnea.1

 

Proven to significantly improve quality of life [1]

  • All predefined primary analyses demonstrated statistically and clinically relevant benefits in favor of patients receiving Tarceva1.
  • In addition, secondary analyses showed that significantly more patients receiving Tarceva had improved global QOL and improvements in most functional domains.1
 
  Secondary endpoints were significantly improved with Tarceva treatment* †1   Global QOL (P<0,0001)
Physical functioning (P=0,01)
Emotional functioning (P=0,01)
Cognitive functioning (P=0,02)

* vs the placebo arm
† Improvements indicate a 10-point or greater increase from baseline (scale of 0 to 100).

 
Tarceva demonstrated significant symptom benefits by prolonging time to progression of symptoms that affect quality of life. [2]
 
  

References 

  1. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2006;24:3831-3837.
  2. Tarceva® (erlotinib) summary of product characteristics, F. Hoffmann-La Roche Ltd., 2007.

Mechanism of action

How Tarceva® works

 Broadband | Dial-up

 Broadband | Dial-up

Tarceva.com

This site is only intended for use by healthcare professionals outside of the US. If you are a US resident, please visit www.tarceva.com.

New indication for Tarceva

Tarceva in maintenance NSCLC therapy